No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: A1 - Approval enfortumab vedotin-ejfv Sensitive : A1	enfortumab vedotin-ejfv Sensitive: A1 - Approval enfortumab vedotin-ejfv Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A1 - Approval pembrolizumab + enfortumab vedotin-ejfv Sensitive : A1	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A1 - Approval pembrolizumab + enfortumab vedotin-ejfv Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	enfortumab vedotin-ejfv Sensitive: A2 - Guideline enfortumab vedotin-ejfv Sensitive : A2	enfortumab vedotin-ejfv Sensitive: A2 - Guideline enfortumab vedotin-ejfv Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A2 - Guideline pembrolizumab + enfortumab vedotin-ejfv Sensitive : A2	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A2 - Guideline pembrolizumab + enfortumab vedotin-ejfv Sensitive : A2
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	SHR-A2102 Sensitive: B - Late Trials SHR-A2102 Sensitive : B	SHR-A2102 Sensitive: B - Late Trials SHR-A2102 Sensitive : B
NECTIN4 expression	Urothelial Cancer	NECTIN4 expression	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C2 – Inclusion Criteria enfortumab vedotin-ejfv Sensitive : C2	enfortumab vedotin-ejfv Sensitive: C2 – Inclusion Criteria enfortumab vedotin-ejfv Sensitive : C2
NECTIN4 expression	Solid Tumor	NECTIN4 expression	Solid Tumor	SBT6290 Sensitive: C2 – Inclusion Criteria SBT6290 Sensitive : C2	SBT6290 Sensitive: C2 – Inclusion Criteria SBT6290 Sensitive : C2
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	enfortumab vedotin-ejfv Resistant: C3 – Early Trials enfortumab vedotin-ejfv Resistant : C3	enfortumab vedotin-ejfv Resistant: C3 – Early Trials enfortumab vedotin-ejfv Resistant : C3
CDKN2B mutation	Urothelial Cancer	CDKN2B mutation	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
TP53 mutation	Urothelial Cancer	TP53 mutation	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
TMB-H	Urothelial Cancer	TMB-H	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	pembrolizumab + enfortumab vedotin-ejfv Sensitive: C3 – Early Trials pembrolizumab + enfortumab vedotin-ejfv Sensitive : C3	pembrolizumab + enfortumab vedotin-ejfv Sensitive: C3 – Early Trials pembrolizumab + enfortumab vedotin-ejfv Sensitive : C3
PD-L1 underexpression	Urothelial Cancer	PD-L1 underexpression	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
KDM6A mutation	Urothelial Cancer	KDM6A mutation	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
HER-2 mutation	Urothelial Cancer	HER-2 mutation	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3	enfortumab vedotin-ejfv Sensitive: C3 – Early Trials enfortumab vedotin-ejfv Sensitive : C3
NECTIN4 underexpression	Urothelial Cancer	NECTIN4 underexpression	Urothelial Cancer	enfortumab vedotin-ejfv Resistant: D – Preclinical enfortumab vedotin-ejfv Resistant : D	enfortumab vedotin-ejfv Resistant: D – Preclinical enfortumab vedotin-ejfv Resistant : D
NECTIN4 overexpression	Triple Negative Breast Cancer	NECTIN4 overexpression	Triple Negative Breast Cancer	9MW2821 Sensitive: D – Preclinical 9MW2821 Sensitive : D	9MW2821 Sensitive: D – Preclinical 9MW2821 Sensitive : D

Nectin-4-targeted antibody-drug conjugate

Nectin-4-targeted antibody-drug conjugate

Associations(17)

Associations
(17)